Is repeated high-dose medroxyprogesterone acetate (MPA) therapy permissible for patients with early stage endometrial cancer or atypical endometrial hyperplasia who desire preserving fertility?
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.